secwatch / observer
8-K filed November 17, 2021, 6:59 PM ET ticker SRPT CIK 0000873303
leadership confidence high sentiment neutral materiality 0.55

Sarepta appoints Stephen Mayo to board, promotes Rodino-Klapac to R&D head, O'Neill departs

Sarepta Therapeutics, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Gilmore O'Neill

Other Named Officer
SRPT · Sarepta Therapeutics, Inc.
Effective
2021-11-30
Filed
November 17, 2021, 6:59 PM ET
On November 15, 2021, the Company and Gilmore O’Neill, M.B., M.M.Sc. mutually agreed to end Dr. O'Neill's employment with the Company, effective as of November 30, 2021
Appointed

Stephen L. Mayo

Director
SRPT · Sarepta Therapeutics, Inc.
Effective
2021-11-16
Filed
November 17, 2021, 6:59 PM ET
On November 16, 2021, the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc. (the "Company") appointed Stephen L. Mayo, Ph.D. as a director of the Company, effective as of November 16, 2021.
Role change

Louise Rodino-Klapac

Head of R&D, Chief Scientific Officer
SRPT · Sarepta Therapeutics, Inc.
Effective
2021-11-16
Filed
November 17, 2021, 6:59 PM ET
On November 16, 2021, Louise Rodino-Klapac, Ph.D., the Company's Chief Scientific Officer, was promoted to Head of R&D, Chief Scientific Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.7

Gilmore O'Neill resigned as other_named_officer at Sarepta Therapeutics, Inc..

Action
resigned
Exact text from the filing
On November 15, 2021, the Company and Gilmore O’Neill, M.B., M.M.Sc. mutually agreed to end Dr. O'Neill's employment with the Company, effective as of November 30, 2021
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen L. Mayo was appointed as Director at Sarepta Therapeutics, Inc..

Action
appointed
Role
Director
Exact text from the filing
On November 16, 2021, the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc. (the "Company") appointed Stephen L. Mayo, Ph.D. as a director of the Company, effective as of November 16, 2021.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Louise Rodino-Klapac changed role as Head of R&D, Chief Scientific Officer at Sarepta Therapeutics, Inc..

Action
promoted
Role
Head of R&D, Chief Scientific Officer
Exact text from the filing
On November 16, 2021, Louise Rodino-Klapac, Ph.D., the Company's Chief Scientific Officer, was promoted to Head of R&D, Chief Scientific Officer.
View on SEC.gov

Sarepta Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0000950170-21-004713
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.